Allogene Expands Pivotal ALPHA3 Cancer Trial to South Korea and Australia
ALLO has more than doubled off its 52-week low of $0.862.
Summary
Allogene Therapeutics announced the expansion of its pivotal Phase 2 ALPHA3 trial for cema-cel in first-line large B-cell lymphoma to South Korea and Australia, increasing global sites from over 60 to over 80. This strategic expansion follows the highly positive interim futility analysis results reported on April 13th, which demonstrated a 58.3% minimal residual disease clearance. The move is expected to accelerate enrollment and global development of cema-cel, leveraging established clinical research infrastructure in these new regions. This is a positive operational step, indicating strong progress and commitment to advancing a key pipeline asset towards a potential Biologics License Application submission. Investors will monitor enrollment progress and the anticipated interim event-free survival analysis in mid-2027.
At the time of this announcement, ALLO was trading at $2.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $801.7M. The 52-week trading range was $0.86 to $4.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.